Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...

Medicaid expansion is associated with lower 2- and 4-year mortality among patients with resectable non-small cell lung cancer ...

In this study, researchers sought to determine whether Medicaid expansion led to improvements in survival for patients with resectable NSCLC.

Data from the non-pivotal stage of the global Phase 3 PRESERVE-003 trial revealed that gotistobart reduced the risk of death by 54% compared to docetaxel chemotherapy. The 12-month survival rate was ...

Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved. Many factors influence the likelihood of a lung cancer cure or long-term survival, ...

Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...

The time of day that cancer drugs are administered could make a big difference to a patient's outcomes, and would be a ...

Yes, lung cancer can be curable — if it’s found early and responds well to treatment. Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved.